Compare Citius Pharmaceuticals Inc (CTXR) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Lamb Weston Holdings Inc trades at $46.67 (market cap $6.42B). The key difference: Lamb Weston Holdings Inc is far larger — about 438.5× Citius Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LW | |
|---|---|---|
Market Cap | $14.64M | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $66.57 |
52-Week Low | $0.53 | $38.48 |
Enterprise Value | $10.86M | $10.38B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Lamb Weston (LW) trades at $46.98, up 1.14% with a bullish technical signal and consistent earnings beats. The company shows strong operational cash flow of $868.3M in 2025 and maintains positive revenue growth, though net income margin declined to 4.61%. Recent news highlights the 'Focus to Win' strategy showing early traction with North America volume gains and cost savings.
Outlook remains cautiously optimistic with analyst consensus price target of $49.33 offering 5% upside. Key risks include ongoing securities litigation and margin pressure from competitive dynamics. Institutional sentiment leans positive with activist involvement signaling potential value creation opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
